Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Conmed (CNMD) EBITDA (2016 - 2026)

Conmed filings provide 17 years of EBITDA readings, the most recent being $15.4 million for Q1 2026.

  • On a quarterly basis, EBITDA rose 105.79% to $15.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $67.6 million, a 39.23% decrease, with the full-year FY2025 number at $59.6 million, down 51.82% from a year prior.
  • EBITDA hit $15.4 million in Q1 2026 for Conmed, down from $19.7 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $48.7 million in Q3 2024 to a low of -$172.6 million in Q2 2022.
  • Median EBITDA over the past 5 years was $19.7 million (2025), compared with a mean of $11.0 million.
  • Biggest five-year swings in EBITDA: tumbled 1072.98% in 2022 and later surged 327.65% in 2024.
  • Conmed's EBITDA stood at $28.9 million in 2022, then grew by 27.72% to $36.9 million in 2023, then dropped by 19.66% to $29.6 million in 2024, then crashed by 33.56% to $19.7 million in 2025, then fell by 21.55% to $15.4 million in 2026.
  • The last three reported values for EBITDA were $15.4 million (Q1 2026), $19.7 million (Q4 2025), and $6.6 million (Q3 2025) per Business Quant data.